Wall Street analysts forecast that Hologic (HOLX) will report quarterly earnings of $1.02 per share in its upcoming release, pointing to a year-over-year decline of 1%. It is anticipated that revenues will amount to $1 billion, exhibiting a decline of 1.6% compared to the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections duri ...

Hologic, Inc.’s (HOLX)   fiscal 2025 second-quarter financial results, set to release on May 1 after the market closes, will likely see a solid performance of its GYN Surgical segment driven by its International strength. Molecular Diagnostics performance is expected to have strongly contributed to the Diagnostics division’s growth. In Breast Health, steady service revenues are expected to have helped offset the capital equipment softness.Meanwhile, check out our analysis to determine if the stock is worth ...

Core Viewpoint - Hologic (HOLX) is expected to report a decline in second-quarter fiscal 2025 earnings and revenues, with earnings estimated at $1.02 per share, reflecting a 0.97% year-over-year decrease, and revenues projected at $1.00 billion, indicating a 1.56% decline year over year [1][2] Earnings Performance - In the last four quarters, Hologic surpassed consensus estimates three times, with an average surprise of 2.53% [2] - The reported earnings history shows a slight variation from estimates, with the most recent quarter ending in December 2024 reporting $1.03 against an estimate of $1.02, resulting in a surprise of 0.98% [3] Earnings Expectations - Hologic has an Earnings ESP of 0.00%, indicating no expected surprise in the upcoming earnings report [4] - The company currently holds a Zacks Rank of 3 (Hold) [4] Challenges Impacting Performance - The company faces challenges such as macroeconomic volatility, supply-chain constraints, cost inflation, and a strengthening U.S. dollar, which are expected to negatively impact performance [5][6] - The Skeletal Health segment is projected to see a significant 32.8% year-over-year decline in sales due to shipment delays [6] Segment Performance - The Breast Health segment is anticipated to experience a 3.6% decline in revenues due to lower sales of capital equipment [7] - The Diagnostics division is expected to show modest growth of 0.5%, driven by strong sales in its core Molecular business [9] - The GYN Surgical segment is likely to see a 3% year-over-year revenue increase, supported by strong international sales [11] Stock Performance - Hologic shares have declined 4.2% over the past 30 days, performing better than the industry average decline of 9% and the S&P 500's 7% decline [12] - The stock is trading at a forward P/E of 13.05X, which is lower than the industry average of 27.41X, indicating a more attractive valuation [16] Investment Thesis - Hologic's molecular diagnostics business has significant growth potential, and the company holds a strong market position in Breast Health with plans for future product launches [19] - Recent acquisitions, such as Endomagnetics and Gynesonics, reflect the company's strong balance sheet and commitment to growth [20] - The company aims for double-digit earnings growth through a combination of steady revenue growth, margin expansion, and strategic acquisitions [20] International Growth Strategy - Hologic is focusing on international growth by going direct in more markets, with the International Surgical business showing over 20% growth [21] - The company expects its international revenues in cytology and STI testing to become significant revenue drivers over time [21] Long-term Outlook - Despite current macroeconomic pressures, Hologic's Diagnostics division is expected to perform well, and the company is well-positioned for long-term growth through its core business performance and acquisitions [22]

Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Cellulite Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Global Cellulite Treatment Market was valued at USD 1.57 billion in 2024 and is expected to reach USD 2.47 billion by 2030 with a CAGR of 7.84% during the forecast period. The global cellulite treatment market is a dynamic and rapidly growing segment within the broader healthcare and wellness i ...

In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. According to Roots Analysis, the IVD market is projected to witness a 6.2% compound annual growth rate through 2035. Two prominent companies with a strong foothold in this space are Hologic (HOLX) and Myriad Genetics (MYGN) . Hologic’s molecular diagnostics offerings specialize in women’s health and acute respirator ...

Core Insights - Hologic appointed Wayde McMillan to its board, enhancing its financial expertise and understanding of the MedTech industry [1][2] - The company's stock performance has been relatively resilient compared to industry peers, with a 7.2% decline over the past month, less than the industry's 10.3% drop [3] Company Developments - Hologic's board now includes a finance veteran, which is expected to positively impact the company's strategic direction [1][2] - The stock saw a 2.6% increase in after-hours trading following the announcement of McMillan's appointment [2] Financial Performance - Hologic's stock has outperformed Medtronic and Abbott, which experienced declines of 11.6% and 9.4%, respectively [3] - The company anticipates a revenue impact of up to $30 million for fiscal 2025 due to external disruptions, including the freezing of U.S. foreign assistance funds [9] Market Challenges - Hologic faces challenges from new tariffs imposed on products manufactured in Costa Rica and Mexico, which could increase operational costs [8] - The company has cut its fiscal 2025 revenue projections by $100 million, now targeting a range of $4.15-$4.20 billion [10] Growth Opportunities - Hologic's Diagnostics division remains a key strength, with growth driven by its Molecular Diagnostics and Biotheranostics lab testing business [14] - The company is focusing on international expansion, particularly in underpenetrated markets, which presents significant growth potential [16][18] Valuation Metrics - Hologic's forward P/E ratio is 13.66X, significantly lower than the industry average of 26.54X, indicating a favorable valuation position [19][21]

Core Insights - Hologic (HOLX) is experiencing growth driven by new product launches in Diagnostics and Breast Health, but macroeconomic challenges and unfavorable foreign exchange (FX) conditions are hindering its overall performance [1][8]. Product Developments - The introduction of the Envision Mammography Platform, the first FDA-approved technology of its kind, is expected to enhance Hologic's offerings with a leading 2.5-second scan time, set for commercial launch next year [2]. - Hologic is launching the next-generation Genius AI Detection PRO solution in the U.S., which builds on the previous version to improve accuracy and efficiency in cancer screening, addressing racial bias concerns in AI-driven diagnoses [3]. Business Performance - The Surgical business is showing strong performance, with over 20% growth in the International Surgical segment in the first quarter of fiscal 2025, indicating optimism for future expansion [4]. - The molecular diagnostics segment is a key revenue driver, contributing 11% to revenues in the first quarter of fiscal 2025, excluding COVID-19 sales, with strong growth in the BV CV/TV assay and core women's health assays [5]. Strategic Initiatives - Hologic is implementing strategies to streamline operations and reduce costs, including targeted investments in marketing campaigns and initiatives to gain market share [6]. Market Challenges - The stock has declined 18.6% over the past year, compared to a 7.7% decline in the industry, but there are expectations for recovery as the company focuses on expanding its diagnostic and breast health offerings [7]. - Concerns about a potential recession and global supply constraints are impacting the company's ability to meet demand and increasing costs [8]. - Hologic has reduced its full-year revenue guidance by $100 million to a range of $4.05 billion to $4.10 billion due to a reassessment of market trends and a stronger U.S. dollar, which is expected to create a $20 million FX headwind for fiscal 2025 [9][12].

Core Viewpoint - Hologic (HOLX) has faced significant stock decline of 24.7% over the past six months, underperforming compared to the industry and S&P 500 [1] - The company is navigating challenges from geopolitical shifts, economic pressures, and internal divisional weaknesses, leading to a cautious fiscal outlook for 2025 [22] Financial Performance - Hologic's stock reached a 52-week low of $60.34, influenced by broader economic pressures and a subdued earnings report [4] - Revenue growth was limited to 0.9% year-over-year, with a $30 million foreign exchange headwind projected for the full year [8] - The company revised its revenue guidance for fiscal 2025 down to $4.05 billion to $4.10 billion, a reduction of $100 million from previous estimates [8] Market Challenges - The company faces uncertainties due to U.S. policy shifts, particularly affecting its partnership with PEPFAR for HIV testing, potentially impacting revenues by up to $30 million [5] - Recent tariffs may challenge profitability for products imported from Mexico, alongside increased production and storage costs due to supply-chain constraints [6] - The Breast Health unit is expected to have a softer year, with a 2.1% decline in sales and a 37.4% drop in Skeletal revenues due to shipment delays [7] Strategic Initiatives - Hologic emphasizes strategic acquisitions to drive growth, including Biotheranostics and Gynesonics, which are expected to enhance margins and expand product offerings [12][13] - The company is focusing on international expansion, particularly in underpenetrated markets, leveraging its strong product portfolio [14][15] Innovations and Opportunities - Hologic is introducing advanced AI-powered breast imaging technologies, such as the Envision platform and Genius AI Detection PRO, which are generating significant market interest [16][17] - The company is well-positioned to capture emerging market opportunities with its innovative offerings and strong brand presence [15] Valuation - Hologic shares are trading at a forward price-to-earnings (P/E) ratio of 13.96X, significantly lower than the industry average of 29.22, indicating a potentially undervalued stock [19]

Core Viewpoint - Hologic reported a mixed performance in its Q1 fiscal 2025 earnings, with adjusted earnings per share surpassing estimates, but revenues showing modest growth and a downward revision in full-year guidance [2][3][13]. Financial Performance - Adjusted earnings per share for Q1 fiscal 2025 were $1.03, reflecting a 5.1% year-over-year increase and exceeding the Zacks Consensus Estimate by 0.9% [2]. - Total revenues reached $1.02 billion, marking a 0.9% year-over-year increase, consistent with the Zacks Consensus Estimate [3]. - U.S. revenues were $757.9 million, up 0.6% year over year, while international revenues totaled $263.9 million, up 1.7% year over year [4]. Segment Performance - Diagnostics segment revenues increased 5.1% year over year to $470.6 million, with a notable 9% increase excluding COVID-19 revenues [5]. - Breast Health segment revenues decreased 2.3% year over year to $369.1 million, attributed to lower sales of mammography capital equipment [7]. - GYN Surgical segment reported a 2.5% year-over-year increase in revenues to $166.3 million [8]. - Skeletal Health segment revenues declined 37.8% year over year to $15.8 million [10]. Operational Metrics - Adjusted gross margin improved by 80 basis points to 61.6%, while adjusted operating margin expanded by 90 basis points to 29.4% [11]. Financial Position - Cash and cash equivalents at the end of Q1 were $1.78 billion, down from $2.16 billion at the end of Q4 fiscal 2024 [12]. - Total long-term debt increased slightly to $2.53 billion from $2.50 billion [12]. Guidance and Outlook - For fiscal 2025, Hologic revised revenue guidance to $4.05-$4.10 billion, down from the previous $4.15-$4.20 billion [13]. - Adjusted earnings per share guidance remains at $4.25-$4.35, with projected growth of 4.2%-6.6% year over year [14]. - For Q2 fiscal 2025, revenue is expected to be between $995 million and $1.01 billion, indicating a year-over-year decline [14][15]. Market Sentiment - Recent estimates for Hologic have been trending downward, indicating a cautious outlook among investors [16][18]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the near term [18].

Core Viewpoint - Hologic has received two significant regulatory approvals, enhancing its product portfolio, while facing challenges reflected in its recent fiscal report, leading to a decline in stock price. Regulatory Approvals - Hologic's Affirm Contrast Biopsy software has received the CE Mark, complementing its FDA clearance from October 2020. The Aptima SARS-CoV-2 assay has achieved FDA's 510k clearance after previously being granted Emergency Use Authorization in May 2020 [1][2][8]. Financial Performance - Hologic's Q1 revenues reached $1.02 billion, aligning with Zacks Consensus Estimate, with a 1% growth target in constant currency. The Diagnostics division grew 9.1% organically, while Breast Health revenues declined by 2.1% [5][6]. - The adjusted gross margin improved by 80 basis points to 61.6%, and adjusted operating margin expanded by 90 basis points to 29.4%. Adjusted EPS was $1.03, exceeding consensus by 0.9% and up 5% year-over-year [6][7]. Stock Performance - Hologic's stock has declined 9.3% year-to-date, underperforming the industry growth of 5.4% and the broader sector's 6.2% rise. The stock closed at $65.01, reflecting a 10.4% drop post-earnings announcement [2][3]. Long-Term Growth Prospects - Hologic has achieved a 4.8% CAGR in revenues over the past decade, with adjusted EPS growing at 10.8% CAGR. The company anticipates continued double-digit earnings growth, supported by steady revenue increases [12][14]. - The Biotheranostics business is a key growth driver, particularly with the Breast Cancer Index test. Hologic aims to diversify its revenue mix, with service revenues in Breast Health now surpassing the gantry business [13][14]. M&A Strategy and Innovation - Hologic plans to leverage M&A to expand into high-growth adjacent markets, having recently acquired Gynesonics and Endomagnetics, contributing to revenue growth [14][15]. - The company is introducing AI-powered diagnostic systems and has plans for the commercial launch of the Envision Platform next year, indicating a focus on innovation [15]. Revised Financial Expectations - Hologic has revised its fiscal 2025 sales expectations down by $100 million to a range of $4.05-$4.10 billion, citing adverse impacts from currency fluctuations and geopolitical challenges [17][19]. - The company expects adjusted EPS between $4.25 and $4.35 for fiscal 2025, despite the challenges faced [19].